\
&
Contact us
Background stories of how others approached and experienced their European Horizon funding trajectory.
Published on | 1 year ago
Programmes HealthThe METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
Read the full article for details
GenderSAFE, funded by Horizon Europe under call topic HORIZON-WIDERA-2023-ERA-01-09, is a project that advances efforts to implement a zero-tolerance approach to gender-based violence in higher education and research in the European Research Area. This overall objective will be achieved through a five-fold strategy. The project exists of a European-wide consortium of six partners. Read more about the GenderSAFE’s five-fold strategy, the role of the Belgian partner Yellow Window and the latest outputs of the project in this testimonial.